Suggestions
Spencer Guthrie
Chief Executive Officer at Attralus
Spencer Guthrie is the Chief Executive Officer of Attralus, a biopharmaceutical company focused on developing therapies for systemic amyloidosis. He has held this position since September 2019. Under his leadership, Attralus aims to transform the treatment landscape for patients suffering from amyloidosis by creating therapeutics that can remove toxic amyloid deposits from the body, which current treatments do not adequately address.12
Professional Background
Guthrie has extensive experience in clinical operations and biopharma strategy. His professional journey includes several notable roles:
- President at Biopharma Strategy Consulting (February 2014 - Present)
- Vice President, Global TTR Strategy at Akcea Therapeutics (March 2018 - April 2019)
- VP, Global Head of Medical Affairs at Prothena Biosciences (July 2016 - July 2017)
- Sr. Director, Head of Clinical Operations at Ultragenyx Pharmaceutical Inc. (June 2012 - July 2014)
- Various leadership roles at Janssen Alzheimer Immunotherapy Research and Development and Elan Pharmaceuticals.1
Education
Guthrie holds a Bachelor's degree from Vanderbilt University and an MBA from the University of California, Irvine. He also earned a Master of Public Health (MPH) from the Johns Hopkins Bloomberg School of Public Health.1
Contributions to Amyloidosis Research
As a co-founder of Attralus, Guthrie is heavily involved in advancing research and development in amyloid-related diseases. His work focuses on innovative approaches to therapeutics that target amyloid fibrils, aiming to improve patient outcomes significantly.34
Highlights
